AFP
HZNP

Ausdal Financial Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ausdal Financial Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,500
Closed -$119K – 1166
2015
Q4 		$119K Buy
+5,500
New +$107K 0.06% 275

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Ausdal Financial Partners's HZNP Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2016, closing a stake of 5,500 shares — an estimated $119K sold.

Ausdal Financial Partners first reported a position in HZNP in Q4 2015 and held it in 1 quarter. The position peaked at $119K in Q4 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 5,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $119K.
  • Ausdal Financial Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $119K in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.